Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

TCRT

+ Watchlist+ Portfolio

Alaunos Therapeutics, Inc.

Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$1.71
52-Week Range
$0.72 – $4.50
Market Cap
$6.69M
P/E (TTM)
—
EPS (TTM)
-1.76
Dividend Yield
0.00%
Advanced Metrics
Price/Book
5.45
PEG Ratio
0.58
Return on Equity
-192.00%
Return on Assets
-80.45%
Gross Margin
0.00%
Operating Margin
-121033.34%
Profit Margin
0.00%
Current Ratio
1.14
Debt/Equity
—
Total Debt
$0.00
Free Cash Flow
$-1.13M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$6.62M

Market Snapshot

About

Alaunos Therapeutics, Inc. is a clinical-stage cell therapy company focused on developing adoptive T cell receptor (TCR) therapies for the treatment of solid tumors. The company engineers patient T cells to recognize and attack cancer cells by targeting specific tumor-associated antigens. Alaunos is advancing multiple TCR programs for various cancer indications.